22 September 2020

AMRA Medical’s Study on MRI-Based Muscle Composition in Diabetes Selected for EASD 2020

AMRA Medical’s Study on MRI-Based Muscle Composition in Diabetes Selected for EASD 2020

AMRA Medical assessed prevalence of sarcopenia, adverse muscle composition, and low functional performance within Type 2 Diabetes and will present at EASD virtual meeting.

Linköping, Sweden, September 22, 2020: AMRA, in partnership with Linköping University, evaluated the prevalence of sarcopenia, low functional performance, and adverse muscle composition (AMC) – measured by magnetic resonance imaging (MRI) – in Type II Diabetes (T2D) and will present the results at the European Association for the Study of Diabetes annual meeting 2020, 21 – 25 September.

The research was based on 9,724 UK Biobank participants and utilized functional measures (e.g. hand grip strength, stair climbing, number of falls), dual energy X-ray absorptiometry, and questionnaire data to determine the prevalence of sarcopenia and low functional performance. AMRA utilized AMRA® Researcher to quantify fat-free muscle volume and muscle fat infiltration from MRI. Each participant was then assigned a personalized muscle volume z-score, calculated using virtual control groups 1 to detect AMC. Prevalence of sarcopenia, low functional performance, and AMC in participants with T2D were compared to those without T2D.

AMRA researchers found that although the prevalence of sarcopenia was similar between those with and without T2D, low functional performance was higher in T2D – reflecting a limitation with the current definition of sarcopenia. Interestingly, AMC was significantly more common in T2D (26%) compared to individuals without T2D (9.5%). The research data indicate that sarcopenia-related issues are much more common in those with T2D compared to those without T2D, but can go undetected by current sarcopenia tools, whereas MRI-based muscle composition provides a more accurate description of a patient’s muscle status.

AMRA will present “Adverse Muscle Composition in T2D – Results from the large UK Biobank Imaging Study”, presentation number 972 at EASD online September 24th at 1:15 pm – 2:15 pm CET during Poster Session: PS 96 Tradition? No! Non-traditional complications of diabetes.

Learn more about AMRA’s research, capabilities, and opportunities for collaboration by attending AMRA’s digital poster presentation at EASD 2020 and visiting www.amramedical.com

 

About AMRA Medical

AMRA is a ground-breaking international digital health company at the forefront of medical imaging and precision medicine. The company has developed a new global standard in body composition assessment, the ability to automatically produce multiple fat and muscle biomarkers with unrivaled precision and accuracy, as well as contextual disease insights – all from a single, rapid, whole-body MRI. AMRA’s aim is to support transformative care and vital decision-making from clinical research to health and wellness.

 

ContactRosemary Shull
SVP Global BD & Marketing
rosemary.shull@amramedical.com

 

1Linge et al, J Gerontol A Biol Sci Med Sci 2020. doi: 10.1093/gerona/glz229

AMRA is a ground-breaking international digital health company at the forefront of medical imaging and precision medicine. The company has developed a new global standard in body composition assessment, the ability to automatically produce multiple fat and muscle biomarkers with unrivaled precision and accuracy, as well as contextual disease insights – all from a single, rapid, whole-body MRI. AMRA was founded in 2010 as a spin-off of Linköping University, Sweden, with the aim to support transformative care and vital decision-making from clinical research to health and wellness.

Contact

Marie Börjesson
Senior Director, Brand & Marketing
marie.borjesson@amramedical.com

comment

Latest News

language

Meet Us Here